Skadden Reps Valeant In $345M Jannsen Unit Buy

Law360, Wilmington (July 15, 2011, 4:38 PM EDT) -- Canada-based Valeant Pharmaceuticals International Inc. said Friday it had agreed to acquire a Jannsen Pharmaceuticals Inc. dermatology unit for $345 million, capping off a $1 billion skin care drug buying spree in the past three weeks.

In the deal, two Valeant subsidiaries — Valeant Pharmaceuticals North America and Valeant International (Barbados) SRL — will pick up Janssen’s Ortho Dermatologics division and its prescription acne medication brands Retin-A Micro and Renova, as well as the foot fungus drug Ertaczo, according to a statement from Valeant.

“With the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.